-+ 0.00%
-+ 0.00%
-+ 0.00%

Citigroup Maintains Buy on Candel Therapeutics, Lowers Price Target to $22

Benzinga·03/13/2026 20:09:14
Listen to the news
Citigroup analyst Yigal Nochomovitz maintains Candel Therapeutics (NASDAQ:CADL) with a Buy and lowers the price target from $24 to $22.